Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation

Journal of Psychiatric Research

Volumn 45, Issue 9, 2011, Pages 1194-1201

  Richtand, Neil M ^a,b,c   Ahlbrand, Rebecca ^a,b   Horn, Paul ^a,c   Stanford, Kevin ^b   Bronson, Stefanie L ^b,c   McNamara, Robert K ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Animal model; Dopamine; First episode psychosis; Maternal; Prodrome; Schizophrenia

Indexed keywords

AMPHETAMINE; PALIPERIDONE; POLYINOSINIC POLYCYTIDYLIC ACID; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNITY; LOCOMOTION; MALE; NONHUMAN; PRENATAL PERIOD; PRIORITY JOURNAL; RAT; RISK FACTOR; SCHIZOPHRENIA;

AMPHETAMINE; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FEMALE; ISOXAZOLES; MOTOR ACTIVITY; POLY I-C; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS;

EID: 80051672617     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.02.007     Document Type: Article

References (68)

1. Abercrombie E.D., Keefe K.A., DiFrischia D.S., Zigmond M.J. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem 1989, 52:1655-1658.
2. Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B., McGlashan T.H., Perkins D.O., et al. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull 2007, 33:665-672.
3. Bakos J., Duncko R., Makatsori A., Pirnik Z., Kiss A., Jezova D. Prenatal immune challenge affects growth, behavior, and brain dopamine in offspring. Ann N Y Acad Sci 2004, 1018:281-287.
4. Bitanihirwe B.K., Weber L., Feldon J., Meyer U. Cognitive impairment following prenatal immune challenge in mice correlates with prefrontal cortical AKT1 deficiency. Int J Neuropsychopharmacol 2010, 1-16.
5. Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav Immun 2010, 24:881-897.
6. Bronson SL, Ahlbrand RL, Horn, PS, Kern JR, Richtand NM. Individual differences in maternal response to immune challenge predict offspring behavior: contribution of maternal, social, and environmental factors. Behav Brain Res 2011; Jan 19. [Epub ahead of print].
7. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167:261-280.
8. Brown A.S., Begg M.D., Gravenstein S., Schaefer C.A., Wyatt R.J., Bresnahan M., et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004, 61:774-780.
9. Brown A.S. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006, 32:200-202.
10. Cannon T.D., Cadenhead K., Cornblatt B., Woods S.W., Addington J., Walker E., et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008, 65:28-37.
11. Carlsson A., Waters N., Waters S., Carlsson M.L. Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev 2000, 31:342-349.
12. Cornblatt B.A., Lencz T., Smith C.W., Olsen R., Auther A.M., Nakayama E., et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007, 68:546-557.
13. Cornblatt B.A. The New York high risk project to the hillside recognition and prevention (RAP) program. Am J Med Genet 2002, 114:956-966.
14. Deutch A.Y., Roth R.H. The determinants of stress-induced activation of the prefrontal cortical dopamine system. Prog Brain Res 1990, 85:367-402.
15. Fernandez-Fernandez R., Navarro V.M., Barreiro M.L., Vigo E.M., Tovar S., Sirotkin A., et al. Effects of chronic hyperghrelinemia on puberty onset and pregnancy outcome in the rat. Endocrinology 2005, 146:3018-3025.
16. Fortier M.E., Kent S., Ashdown H., Poole S., Boksa P., Luheshi G.N. The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 2004, 287:R759-R766.
17. Gilmore J.H., Jarskog L.F., Vadlamudi S. Maternal poly I: C exposure during pregnancy regulates TNF alpha, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat. J Neuroimmunol 2005, 159:106-112.
18. Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., Lopez-Gimenez J.F., et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452:93-97.
19. Hafner H., Maurer K., Ruhrmann S., Bechdolf A., Klosterkotter J., Wagner M., et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci 2004, 254:117-128.
20. Hooks M.S., Kalivas P.W. The role of mesoaccumbens-pallidal circuitry in novelty-induced behavioral activation. Neuroscience 1995, 64:587-597.
21. Koros C., Boukouvalas G., Gerozissis K., Kitraki E. Fat diet affects leptin receptor levels in the rat cerebellum. Nutrition 2009, 25:85-87.
22. Limosin F., Rouillon F., Payan C., Cohen J.M., Strub N. Prenatal exposure to influenza as a risk factor for adult schizophrenia. Acta Psychiatr Scand 2003, 107:331-335.
23. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000, 23:223-239.
24. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T., Woods S.W., et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006, 163:790-799.
25. McGlashan T.H. Early detection and intervention in schizophrenia: research. Schizophr Bull 1996, 22:327-345.
26. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002, 59:921-928.
27. Mednick S.A., Machon R.A., Huttunen M.O., Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1988, 45:189-192.
28. Meyer U., Feldon J. Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res 2009, 204:322-334.
29. Meyer U., Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 2010, 90:285-326.
30. Meyer U., Feldon J., Schedlowski M., Yee B.K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 2005, 29:913-947.
31. Meyer U., Nyffeler M., Yee B.K., Knuesel I., Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008, 22:469-486.
32. Meyer U., Spoerri E., Yee B.K., Schwarz M.J., Feldon J. Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental Mouse model of schizophrenia. Schizophr Bull 2008, 36:607-623.
33. Morrison A.P., French P., Walford L., Lewis S.W., Kilcommons A., Green J., et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004, 185:291-297.
34. Murray R.M., Jones P., O'Callaghan E., Takei N., Sham P. Genes, viruses and neurodevelopmental schizophrenia. J Psychiatr Res 1992, 26:225-235.
35. Ozawa K., Hashimoto K., Kishimoto T., Shimizu E., Ishikura H., Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 2006, 59:546-554.
36. Parikh V., Terry A.V., Khan M.M., Mahadik S.P. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology (Berl) 2004, 172:365-374.
37. Patterson P.H. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009, 204:313-321.
38. Penner J.D., Brown A.S. Prenatal infectious and nutritional factors and risk of adult schizophrenia. Expert Rev Neurother 2007, 7:797-805.
39. Piontkewitz Y., Assaf Y., Weiner I. Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry 2009, 66:1038-1046.
40. Piontkewitz Y., Arad M., Weiner I. Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 2010, May 3. [Epub ahead of print].
41. Pritchard L.M., Logue A.D., Hayes S., Welge J.A., Xu M., Zhang J., et al. 7-OH-DPAT and PD 128907 Selectively Activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology 2003, 28:100-107.
42. Rebec G.V., Christensen J.R., Guerra C., Bardo M.T. Regional and temporal differences in real-time dopamine efflux in the nucleus accumbens during free-choice novelty. Brain Res 1997, 776:61-67.
43. Rebec G.V., Grabner C.P., Johnson M., Pierce R.C., Bardo M.T. Transient increases in catecholaminergic activity in medial prefrontal cortex and nucleus accumbens shell during novelty. Neuroscience 1997, 76:707-714.
44. Rebec G.V. Real-time assessments of dopamine function during behavior: single-unit recording, iontophoresis, and fast-scan cyclic voltammetry in awake, unrestrained rats. Alcohol Clin Exp Res 1998, 22:32-40.
45. Richtand N.M., McNamara R.K. Serotonin and dopamine interactions in psychosis prevention. Prog Brain Res 2008, 172:141-153.
46. Richtand N.M., Taylor B., Welge J.A., Ahlbrand R., Ostrander M.M., Burr J., et al. Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology 2006, 31:77-89.
47. Richtand N.M., Welge J.A., Logue A.D., Keck P.E., Strakowski S.M., McNamara R.K. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007, 32:1715-1726.
48. Richtand N.M., Welge J.A., Logue A.D., Keck P.E., Strakowski S.M., McNamara R.K. Role of serotonin and dopamine receptor binding in antipsychotic efficacy. Prog Brain Res 2008, 172:155-175.
49. Romero E., Ali C., Molina-Holgado E., Castellano B., Guaza C., Borrell J. Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics. Neuropsychopharmacology 2007, 32:1791-1804.
50. Romero E., Guaza C., Castellano B., Borrell J. Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol Psychiatry 2008, 15:372-383.
51. Rosengarten H., Quartermain D. Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats. Pharmacol Biochem Behav 2002, 72:575-579.
52. Roth B.L., Lopez E., Beischel S., Westkaemper R.B., Evans J.M. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 2004, 102:99-110.
53. Segal D.S., Kuczenski R. Behavioral pharmacology of amphetamine. Amphetamine and its analogues: pharmacology, toxicology, and abuse 1994, 115-150. Academic Press, Orlando, FL. A.K. Cho, D.S. Segal (Eds.).
54. Shi L., Fatemi S.H., Sidwell R.W., Patterson P.H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 2003, 23:297-302.
55. Sorg B.A., Kalivas P.W. Effects of cocaine and footshock stress on extracellular dopamine levels in the ventral striatum. Brain Res 1991, 559:29-36.
56. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000, 24:417-463.
57. Takei N., Mortensen P.B., Klaening U., Murray R.M., Sham P.C., O'Callaghan E., et al. Prenatal exposure to influenza and the development of schizophrenia: is the effect confined to females?. Am J Psychiatry 1994, 151:117-119.
58. Takei N., Sham P., O'Callaghan E., Murray G.K., Glover G., Murray R.M. Relationship between in utero exposure to influenza epidemics and risk of schizophrenia in Denmark. Biol Psychiatry 1996, 40:817-824.
59. Terry A.V., Gearhart D.A., Mahadik S.P., Warsi S., Davis L.W., Waller J.L. Chronic exposure to typical or atypical antipsychotics in rodents: temporal effects on central alpha7 nicotinic acetylcholine receptors. Neuroscience 2005, 136:519-529.
60. Tsuang M.T., Stone W.S., Tarbox S.I., Faraone S.V. Treatment of nonpsychotic relatives of patients with schizophrenia: six case studies. Am J Med Genet 2002, 114:943-948.
61. Vuillermot S., Weber L., Feldon J., Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010, 30:1270-1287.
62. Welge J.A., Richtand N.M. Regression modeling of rodent locomotion data. Behav Brain Res 2002, 128:61-69.
63. Woods S.W., Breier A., Zipursky R.B., Perkins D.O., Addington J., Miller T.J., et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003, 54:453-464.
64. Woods S.W., Tully E.M., Walsh B.C., Hawkins K.A., Callahan J.L., Cohen S.J., et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 2007, 51:s96-101.
65. Wright P., Murray R.M. Schizophrenia: prenatal influenza and autoimmunity. Ann Med 1993, 25:497-502.
66. Zicha J., Kunes J. Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev 1999, 79:1227-1282.
67. Zuckerman L., Weiner I. Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology (Berl) 2003, 169:308-313.
68. Zuckerman L., Rehavi M., Nachman R., Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 2003, 28:1778-1789.